{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "SEK", "exchange": "IOB", "shortName": "ONCOPEPTIDES AB ONCOPEPTIDES OR", "longName": "Oncopeptides AB (publ)", "market": "gb_market", "marketState": "CLOSED", "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -4.11, "sharesOutstanding": 90368704, "bookValue": 3.121, "fiftyDayAverage": 10.43073, "fiftyDayAverageChange": -2.29673, "fiftyDayAverageChangePercent": -0.22018881, "twoHundredDayAverage": 16.33537, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "regularMarketChangePercent": 2.896896, "regularMarketPrice": 8.134, "regularMarketChange": 0.22899961, "regularMarketTime": 1683299825, "regularMarketDayHigh": 8.176, "regularMarketDayRange": "8.176 - 8.176", "regularMarketDayLow": 8.176, "regularMarketVolume": 39334, "regularMarketPreviousClose": 7.905, "bid": 7.728, "ask": 8.54, "fullExchangeName": "IOB", "financialCurrency": "SEK", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 5357, "averageDailyVolume10Day": 1974, "fiftyTwoWeekLowChange": 0.12599945, "fiftyTwoWeekLowChangePercent": 0.015734196, "fiftyTwoWeekRange": "8.008 - 50.44", "fiftyTwoWeekHighChange": -42.306, "fiftyTwoWeekHighChangePercent": -0.8387391, "fiftyTwoWeekLow": 8.008, "fiftyTwoWeekHigh": 50.44, "twoHundredDayAverageChange": -8.201369, "twoHundredDayAverageChangePercent": -0.5020621, "marketCap": 739341568, "priceToBook": 2.606216, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "firstTradeDateMilliseconds": 1488528000000, "priceHint": 2, "symbol": "0RN4.IL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Vastra Tradgardsgatan 15", "city": "Stockholm", "zip": "111 53", "country": "Sweden", "phone": "46 86 15 20 40", "website": "https://www.oncopeptides.com/sv", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jakob  Lindberg Med. Lic", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 7260000, "fmt": "7.26M", "longFmt": "7,260,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Monica  Shaw M.D.", "age": 43, "title": "Chief Exec. Officer", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Rolf  Larsson M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Rolf  Lewensohn M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Joachim  Gullbo M.D., MSc Pharm, Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kristina  Luthman Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Hans  Ehrsson M.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter  Nygren", "age": 63, "title": "Founder", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Holger  Lembrer M.Sc.", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1984, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Eva  Nordstr\u00f6m M.Sc., MSc Pharm", "age": 52, "title": "COO & Deputy MD", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}